Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABE8e-SpWT is an adenine base editor (ABE) consisting of an evolved deoxyadenosine deaminase (ABE8e) fused to a catalytically impaired Streptococcus pyogenes Cas9 (SpCas9) protein, typically a nickase. This CRISPR-based tool is designed to perform precise A•T to G•C base pair conversions without inducing double-strand breaks. In the context of X-linked hyper-IgM syndrome (XHIM), ABE8e-SpWT is utilized to correct pathogenic mutations in the CD40L gene (such as the c.658C>T mutation) in patient-derived hematopoietic stem and progenitor cells (HSPCs) and T cells. By restoring functional CD40L expression, the therapy enables B cell class switching and immune reconstitution, offering a potentially curative approach with improved safety over traditional lentiviral gene addition strategies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ABE8e-SpWT base editor.